Monte Rosa Therapeutics (GLUE) holders report sub‑5% stakes in amended 13G

Rhea-AI Filing Summary

Monte Rosa Therapeutics, Inc. is the subject of an amended Schedule 13G filing by Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen regarding holdings of its common stock (CUSIP 61225M102). The reporting persons collectively report beneficial ownership below five percent of the outstanding common stock.

Certain reporting persons beneficially own 3,549,539 shares, representing 4.2% of the class, and Averill Master Fund, Ltd. beneficially owns 3,215,486 shares, or 3.8% of the class. For each reporting person, there is no sole voting or dispositive power; all voting and dispositive authority over these shares is described as shared. The reporting persons state that they disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.

Key Figures

Shares beneficially owned (certain reporting persons): 3,549,539 shares Ownership percentage (certain reporting persons): 4.2% Averill Master Fund shares: 3,215,486 shares +2 more

5 metrics

Shares beneficially owned (certain reporting persons) 3,549,539 shares Beneficial ownership of Monte Rosa common stock representing 4.2% of the class

Ownership percentage (certain reporting persons) 4.2% Percent of Monte Rosa common stock class beneficially owned

Averill Master Fund shares 3,215,486 shares Averill Master Fund, Ltd. beneficial ownership of Monte Rosa common stock

Averill Master Fund ownership percentage 3.8% Percent of Monte Rosa common stock class held by Averill Master Fund, Ltd.

Sole voting power (all reporting persons) 0 shares No sole power to vote or direct the vote over reported shares

Key Terms

beneficial ownership, shared voting power, shared dispositive power, parent holding company, +1 more

5 terms

beneficial ownership financial

"Each Reporting Person disclaims beneficial ownership of the reported securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

shared voting power financial

"Shared Voting Power 3,549,539.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 3,549,539.00"

parent holding company financial

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

pecuniary interest financial

"disclaims beneficial ownership ... except to the extent of his, her or its pecuniary interest"

FAQ

What stake in Monte Rosa Therapeutics (GLUE) does Montanova-related filers report in this Schedule 13G/A?

The filing reports that certain related reporting persons beneficially own 3,549,539 shares of Monte Rosa common stock, representing 4.2% of the class, with shared voting and dispositive power over all such shares and no sole authority.

How many Monte Rosa Therapeutics (GLUE) shares does Averill Master Fund, Ltd. report owning?

Averill Master Fund, Ltd. reports beneficial ownership of 3,215,486 shares of Monte Rosa common stock, representing 3.8% of the class. The fund has no sole voting or dispositive power and instead shares both voting and dispositive authority over these shares.

Are the reporting persons in this Monte Rosa Therapeutics (GLUE) Schedule 13G/A above or below 5% ownership?

Each reporting person indicates ownership of 5 percent or less of Monte Rosa’s common stock. Item 5 is marked to reflect ownership of five percent or less of the class, and stated beneficial ownership percentages are 4.2% and 3.8%.

Do the Monte Rosa Therapeutics (GLUE) reporting persons have sole or shared voting power over the shares?

The reporting persons disclose 0 shares with sole voting or dispositive power and only shared voting and dispositive power over their reported holdings. All authority to vote or dispose of the shares is characterized as shared among the relevant entities or persons.

What disclaimer about beneficial ownership do the Monte Rosa Therapeutics (GLUE) reporting persons include?

They state that each reporting person disclaims beneficial ownership of the reported securities except to the extent of his, her, or its pecuniary interest. They also clarify that this report is not an admission of beneficial ownership for Section 16 or any other purpose.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:29 PM Accepted by SEC EDGAR 08/14/2026 - 04:23 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Monte Rosa Therapeutics, Inc.

(Name of Issuer)

Common stock, par value $0.0001 per share

(Title of Class of Securities)

61225M102

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 61225M102

1

Names of Reporting Persons

Montanova Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,549,539.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,549,539.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,549,539.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 61225M102

1

Names of Reporting Persons

Averill Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,215,486.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,215,486.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,215,486.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.8 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 61225M102

1

Names of Reporting Persons

Aaron Cowen

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,549,539.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,549,539.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,549,539.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Monte Rosa Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 321 Harrison Avenue, Suite 900, Boston, MA 02118
Item 2.
(a)	Name of person filing: Montanova Capital, LLC Averill Master Fund, Ltd. Aaron Cowen
(b)	Address or principal business office or, if none, residence: Montanova Capital, LLC 11 E 26th Street, 16th Floor New York, New York 10010 United States of America Averill Master Fund, Ltd. c/o Maples Corporate Services Limited P.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Aaron Cowen c/o Montanova Capital, LLC 11 E 26th Street, 16th Floor New York, New York 10010 United States of America
(c)	Citizenship: Montanova Capital, LLC - Delaware Averill Master Fund, Ltd. - Cayman Islands Aaron Cowen - United States
(d)	Title of class of securities: Common stock, par value $0.0001 per share
(e)	CUSIP No.: 61225M102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Montanova Capital, LLC - 3,549,539 Averill Master Fund, Ltd. - 3,215,486 Aaron Cowen - 3,549,539
(b)	Percent of class: Suvretta Capital Management, LLC - 4.2% Averill Master Fund, Ltd. - 3.8% Aaron Cowen - 4.2%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0
	(ii) Shared power to vote or to direct the vote: Montanova Capital, LLC - 3,549,539 Averill Master Fund, Ltd. - 3,215,486 Aaron Cowen - 3,549,539
	(iii) Sole power to dispose or to direct the disposition of: Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0
	(iv) Shared power to dispose or to direct the disposition of: Montanova Capital, LLC - 3,549,539 Averill Master Fund, Ltd. - 3,215,486 Aaron Cowen - 3,549,539
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Please see Exhibit B attached hereto.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Montanova Capital, LLC

Signature:	/s/ Andrew Nathanson
Name/Title:	Andrew Nathanson, General Counsel and Chief Compliance Officer
Date:	08/14/2026

Averill Master Fund, Ltd.

Signature:	/s/ Andrew Nathanson
Name/Title:	Andrew Nathanson, Authorized Signatory
Date:	08/14/2026

Aaron Cowen

Signature:	/s/ Aaron Cowen
Name/Title:	Aaron Cowen
Date:	08/14/2026

Comments accompanying signature: * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.

Exhibit Information

Exhibit A - Joint Filing Agreement Exhibit B - Control Person Identification